|
Source: Chasing Markets
Sponsored Content By: Resultz Media
1:19 1/7/2019
The marijuana revolution is in full swing and 2019 will go down as
another incredible year of growth for marijuana stocks.
The next company that may land in the spotlight could be
Resinco Capital
Partners Inc. (OTC: RSCZF) (CSE: RIN), a medical marijuana pharmaceutical
company that is focusing on repairing vital organs by combining
cannabinoids and an endogenous trigger of repair (HMGB1).
In October 2018, Resinco Capital acquired
49% of UK based pharma company ReFormation Pharmaceuticals in an
all stock deal with the option to exercise future warrants. Rescino
is a global investment company looking to expand into the
cannabis/pharma sector.
The growth of the marijuana industry has been very rapid in the
last two years. Since 2016, marijuana has been legalized in over 29
states. Support for marijuana legislation in the U.S. is also at
its highest ever according to the latest Gallup poll.
Tilray, a Canadian pharmaceutical and cannabis company, made its
debut on the NASDAQ this summer and soared from around $20 to as
high as $300. Medical marijuana company Canopy Growth went from
under $25 in August to over $52 in September, more than
doubling.
Traders were celebrating the fact that the maker of Corona beer
decided to invest a whopping $4 billion into the company. If that
isn't confidence in the future of the marijuana industry, then what
is?
Pot stocks may have experienced a healthy pullback recently after
Canada legalized recreational marijuana on October 17th, but the
gains have still been incredible this year and what could still be
expected may blow these gains out of the water. Grand View
Research has predicted that the global legal marijuana market is
expected to reach a staggering $146.4 billion by end of
2025.
Resinco Capital
Partners Inc. (OTC: RSCZF) (CSE: RIN), has been developing a new concept:
that the body's own stem cells that induce repair of tissues can be
made to function more efficiently. This is very exciting and is
something that could really shake up the medical arena.
Over the years, research after research has shown that marijuana is
beneficial in the treatment of many conditions which include
cancer, multiple sclerosis, epilepsy, arthritis, anxiety, IBS, and
PTSD.
Epidiolex, the very first FDA-approved cannabis-based drug just
became available in the U.S. at the start of November. When it
gained FDA approval this past summer, it was a validation that the
world is now ready for cannabinoid medicine.
The world could be more than ready for what Resinco Capital Partners Inc.
(OTC: RSCZF) (CSE: RIN), is bringing to the table...
Resinco Capital
Partners Inc. (OTC: RSCZF) (CSE: RIN) is a medical marijuana
pharmaceutical company headquartered in Toronto, ON with its
research and development team at the University of Oxford.
The company is led by world class scientist, CEO and CSO, Professor
Jagdeep Nanchahal, of the University of Oxford. Signals that the
body's own stem cells that induce repair of tissues can be made to
function more efficiently, have been identified by Prof.
Nanchahal's team.
Ground breaking research by the company's founders has led to the
discovery of an endogenous molecule that primes the body's own stem
cells from a diverse range of tissues to accelerate repair and
regeneration following acute or chronic injury.
The global stem cells market was worth $5.17 billion in 2017 and is
projected to grow to $9.03 billion by 2023. Stem cell therapy has
become the standard of care for many blood disorders, but cellular
therapy for solid organs has not yet yielded the anticipated
benefits.
Prof. Nanchahal's work on complex fractures has led to the
identification of a highly conserved physiological pathway whereby
a protein released by damaged cells accelerates repair and
regeneration of multiple tissues.
Administration of only a single dose of the protein is effective
across a range of disorders by targeting the body's own stem
cells.
Administration of this protein to mice with injuries has been shown
to speed up the healing of bone fractures, restoration of blood
formation in bone marrow after chemotherapy, and repair of damaged
skeletal muscle.
This is a disruptive technology which will deliver a first in class
therapeutic!
Resinco Capital
Partners Inc. (OTC: RSCZF) (CSE: RIN) is considered a 'second generation’
medicinal marijuana company with considerable potential to help
solve major medical unmet needs.
The company will be controlling inflammation first, and then
helping the stem cells to repair the damaged tissues. For
controlling inflammation, the company will use synthetic
non-psychoactive cannabinoids and will access the next generation
product from CannBioRex to assess the efficacy of combination
therapy in its mouse model.
The repair of major tissues will be another benefit of properly
researching and developing the medical activities of cannabis-based
products.
The Company’s research pipeline will deliver further IP based on
composition of matter and has a comprehensive work package of
testing in animal models of diseases where no comparative treatment
exists.
As data accrues, the company will be filing patent applications
that are licensed from the University of Oxford for the various
clinical conditions that the company is testing in animal models.
The company already has preliminary data for myocardial infarction
(heart attack) and are starting experiments in a model of type 1
diabetes.
Cardiovascular disease is the leading cause of death in the Western
World. The company's preliminary data shows that a single injection
of HMGB1 leads to more than 50% improvement in heart function and
similar reduction in damaged tissue in a mouse model.
Data has also shown that HMGB1 promotes regeneration if given up to
4 hours after injury. There is a huge commercial opportunity given
that the average time for a person to reach a hospital in the USA
following a heart attack is 3 hours.
Mutiple ongoing trials for products are going on that would reduce
the autoimmune damage when it comes to diabetes. However, there is
no current treatment that promotes beta cell regeneration yet.
The company also is focusing on Osteoarthritis, Parkinson's
Disease, and liver injury and additionally is working on obtaining
data that will allow the company to file on novel composition of
matter which will give them a unique molecule to progress to
clinical trials.
The veterinary industry could also be a major market for the
company as fractures of limbs are common in dogs and there is yet
an approved product to accelerate healing.
Resinco Capital
Partners Inc. (OTC: RSCZF) (CSE: RIN) will be working with PetCanna
Pharma, a sister company, to develop a therapeutic for accelerating
fracture healing in animals using Reformation IP. Regulatory
hurdles are lower in veterinary medicine compared to humans so the
company will be able to license the product for a quick financial
return.
The biotech sector is comprised of several huge pharma companies
that are developing CBD treatments in various delivery forms.
- GW Pharmaceuticals with Epidiolex
- Zynerba with a CBD "Patch" to treat refractory epilepsy,
osteroarthritis, PTSD, and cancer related pain
- Axim Biotechnologies has CBD based chewing gums to treat
several different conditions
- Insys Therapeutics has a sublingual CBD spray
- Nemus Bioscience is using various CBD extracts to treat
glaucoma and other eye pathologies.
Last year there were several big takeovers in the biotech space
including Gilead Sciences' acquisition of Kite Pharma for $11.9
billion and Johnson & Johnson acquiring Actelion for $30
billion.
Resinco Capital
Partners Inc. (OTC: RSCZF) (CSE: RIN) has a comprehensive work package of
testing in animal models of diseases where no comparative treatment
exists. This makes the company a viable candidate for takeover by
large pharma players.
Marijuana has become a very hot category and one of the top
industries to be watching. What Resinco Capital Partners Inc.
(OTC: RSCZF) (CSE: RIN) is doing could soon have Wall
Street really buzzing...
Disclaimer: Pursuant to an agreement between Resultz Media and
Chasing Markets, we were hired to publicly disseminate information
about (( RSCZF )) including on the Website and other media
including Facebook and Twitter. We were paid $3,000 in cash from
Resultz Media. We own zero shares of (( OTC: RSCZF )) which we
purchased in the open market. We may buy or sell additional shares
of ((OTC: RSCZF )) in the open market at any time, including
before, during or after the Website and Information, provide public
dissemination of favorable Information.
Source: Chasing Markets
Sponsored Content By: Resultz Media
|